News | Ablation Systems | May 17, 2018

CardioFocus Announces Successful Live Case Featuring HeartLight X3 System

Next-generation technology for atrial fibrillation showcased at the 21st Annual Prague Workshop on Catheter Ablation

CardioFocus Announces Successful Live Case Featuring HeartLight X3 System

May 17, 2018 — Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during the annual Prague Workshop on Catheter Ablation, April 21-24 in Prague, Czech Republic.

HeartLight X3 is designed to deliver rapid, continuous, 360-degree lesions for pulmonary vein isolation (PVI) to treat atrial fibrillation. The system does so by building upon the advanced features of the current HeartLight Endoscopic Ablation System — direct tissue visualization, titratable laser energy and compliant balloon technology. The system offers a new "RAPID mode" that leverages a precise motor control system to enable uninterrupted, high-speed lesion creation.

The procedure, broadcast live during the workshop, demonstrated the potential of the HeartLight X3 system. Successful PVI was achieved with a total energy delivery time of under 20 minutes. The case was performed by Petr Neužil, M.D., Ph.D., head of the Department of Cardiology at Na Homolce Hospital in Prague, Czech Republic, and Vivek Y. Reddy, M.D., director of cardiac electrophysiology and Helmsley Trust Professor of Medicine at The Icahn School of Medicine at Mount Sinai. It was part of the ongoing clinical evaluation of the HeartLight X3 System.

"The HeartLight X3 System is demonstrating an unprecedented combination of flexibility and speed," said Neužil "The HeartLight Excalibur Balloon enables wide areas of tissue contact outside of the pulmonary veins, allowing for the system's new RAPID mode to create never-seen-before circumferential, transmural lesion sets. RAPID mode allows for titratable, high-power energy delivery that enables fast ablations. The HeartLight X3 System truly holds the potential to be a breakthrough technology in the AF ablation space."

More than 33 million patients worldwide suffer from AF.1 The most common type of cardiac rhythm disorder, AF prevents blood from being pumped efficiently, which can lead to stroke, weakness, breathlessness, fainting and a significant reduction in quality of life. PVI with the HeartLight X3 System utilizes laser energy to create lines of scar tissue to block abnormal electrical pathways that cause AF.

The clinical evaluation of the HeartLight X3 System is planned to continue throughout 2018, with regulatory submissions to occur thereafter.

The HeartLight X3 System is investigational and not available for sale.

For more information:



1 Chugh SS, Havmoeller R, Narayanan K, et al.; Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47.


Related Content

Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath
Technology | Ablation Systems | May 08, 2018
Biosense Webster Inc. announced its Carto Vizigo Bi-directional Guiding Sheath is now available in the United States....
Stereotaxis and Acutus Medical Announce Strategic Collaboration
News | Ablation Systems | May 04, 2018
Stereotaxis and Acutus Medical announced a strategic collaboration to integrate the Stereotaxis Niobe Magnetic...
Medtronic Cryoballoon Shows Positive Results for Patients With Persistent Atrial Fibrillation
News | Ablation Systems | April 12, 2018
Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance...
Boston Scientific Acquires Securus Medical Group Inc.
News | Ablation Systems | April 04, 2018
Boston Scientific Corp. announced the acquisition of Securus Medical Group Inc., a privately-held company that has...
Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems | December 08, 2017
December 7, 2017 — Stereotaxis Inc.
Overlay Init